Abstract
Twenty-four consecutive HIV-positive patients affected byToxoplasma gondii encephalitis received trimethoprim-sulfamethoxazole (cotrimoxazole) as acute-phase treatment. Two dosage regimens of cotrimoxazole were used: 40 mg/kg/day (12 patients) or 120 mg/kg/day (12 patients) of total compound (trimethoprim plus sulfamethoxazole). Clinical and radiological responses to treatment were evaluated, and the product-limit method for survival data analysis was used. Eighteen of 24 patients showed both a clinical and radiological response (75 % response rate). There were no differences in response rates between patients receiving the two dosage regimens of cotrimoxazole. Adverse reaction consisted of leukopenia (two cases) and skin rash (three cases) which led to the discontinuation of the drug in one case. These results suggest that a randomized, controlled clinical trial should be carried out comparing cotrimoxazole versus sulfadiazine-pyrimethamine in AIDS patients withToxoplasma gondii encephalitis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Luft BJ, Conley F, Remington JS, Laverdiere M, Wagner KF, Levine JF, Craven PC, Stamberg DA, File TM, Rice N, Meunier-Carpentier F: Outbreak of central nervous system toxoplasmosis in Western Europe and North America. Lancet 1983, i: 781–783.
Grossman PL, Remington JS: The effect of trimethoprim and sulfamethoxazole onToxoplasma gondii in vitro and in vivo. American Journal of Tropical Medicine and Hygiene 1979, 28: 445–455.
Derouin F, Chastang C: In vitro effects of folate inhibitors onToxoplasma gondii. Antimicrobial Agents and Chemotherapy 1989, 33: 1753–1759.
Terragna A, Rossolini A, Cellesi C, Figura N, Barbieri A: Activity of the combination trimethoprim-sulfa-methoxazole on experimental toxoplasmosis. Arzneimittel-Forschung (Drug Research) 1973, 23: 1328–1331.
Nguyen BT, Stadtsbaeder S: Comparative effects of cotrimoxazole and spiramycin in pregnant mice infected withToxoplasma gondii (Beverley strain). British Journal of Pharmacology 1985, 85: 713–716.
Harper JS, London WT, Sever JL: Five drug regimens for treatment of acute toxoplasmosis in squirrel monkeys. American Journal of Tropical Medicine and Hygiene 1985, 34: 50–57.
Domart A, Robineau N, Carbon C: La toxoplasmose acquisé: une nouvelle chimiothérapie: l'association sulfaméthoxazole-triméthoprime. Nouvelle Presse Médicale 1973, 2: 321–322.
Norrby R, Eilard T, Svedheim AS, Lycke E: Treatment of toxoplasmosis with trimethoprim-sulfamethoxazole. Scandinavian Journal of Infectious Diseases 1975, 7: 72–75.
Nye FJ: Treating toxoplasmosis. Journal of Antimicrobial Chemotherapy 1979, 5: 244–246.
Nguyen BT, Stadtsbaeder S: Avenir thérapeutique du triméthoprime-sulfaméthoxazole dans la toxoplasmose. Presse Médicale 1983, 12: 331–333.
Haverkos HW andthe Toxoplasma Encephalitis Study Group: Assessment of therapy forToxoplasma encephalitis. American Journal of Medicine 1987, 82: 907–914.
Navia BA, Petito CK, Gold JWM, Cho E-S, Jordan BD, Price RW: Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome. Clinical and neuropathological findings in 27 patients. Annals of Neurology 1986, 19: 224–238.
Potasman I, Resnick L, Luft BJ, Remington JS: Intrathecal production of antibodies againstToxoplasma gondii in patients with toxoplasmic encephalitis and the acquired immunodeficiency syndrome. Annals of Internal Medicine 1988, 108: 49–51.
Lee ET: Statistical methods for survival data analysis. Lifetime Learning Publication, Belmont, California 1980.
Vollmer TL, Waldor MK, Steinman L, Conley FK: Depletion of T4+ lymphocytes with monoclonal antibody reactivates toxoplasmosis in the central nervous system: a model of superinfection in AIDS. Journal of Immunology 1987, 138: 3737–3741.
Canessa A, Pistoia V, Roncella S, Merli A, Melioli G, Terragna A, Ferrarini M: An in vitro model forToxoplasma infection in man. Interaction between CD4+ monoclonal T cells and macrophages results in killing of trophozoites. Journal of Immunology 1988, 140: 3580–3588.
Del Bono V, Canessa A, Bruzzi P, Fiorelli MA, Terragna A: Significance of specific immunoglobulin M in the chronological diagnosis of 38 cases of toxoplasmic lymphadenopathy. Journal of Clinical Microbiology 1989, 27: 2133–2135.
Luft BJ, Remington JS: Toxoplasmic encephalitis. Journal of Infectious Diseases 1988, 157: 1–6.
Cohn JA, McMeeking A, Cohen W, Jacobs J, Holzman RS: Evaluation of the policy of empiric treatment of suspectedToxoplasma encephalitis in patients with the Acquired Immunodeficiency Syndrome. American Journal of Medicine 1989, 86: 521–527.
Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot GA, Marche C, Vedrenne C, Vilde JL: Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. American Journal of Medicine 1988, 84: 94–100.
Gordin FM, Simon GL, Wosfy CB: Adverse reactions to trimethoprim sulfamethoxazole in acquired immunodeficiency syndrome. Annals of Internal Medicine 1984, 100: 495–499.
De Hovitz JA, Johnson WD, Pape WJ: Cutaneous reactions to trimethoprim-sulfamethoxazole in Haitians. Annals of Internal Medicine 1985, 103: 479–480.
Pape WJ, Vardier RI, Johnson WD: Treatment and prophylaxis ofIsospora belli infection in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 1989, 320: 1044–1047.
Author information
Authors and Affiliations
Additional information
Deceased.
Rights and permissions
About this article
Cite this article
Canessa, A., Del Bono, V., De Leo, P. et al. Cotrimoxazole therapy ofToxoplasma gondii encephalitis in AIDS patients. Eur. J. Clin. Microbiol. Infect. Dis. 11, 125–130 (1992). https://doi.org/10.1007/BF01967063
Issue Date:
DOI: https://doi.org/10.1007/BF01967063